Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Among 387 men whose disease had progressed during previous treatment with a next-generation hormonal agent, those initially assigned to olaparib had longer overall survival vs those assigned to enzalutamide or abiraterone plus prednisone (17.3 vs 14.0 months, respectively).

New England Journal of Medicine